Premium
Meal Fat Storage in Subcutaneous Adipose Tissue: Comparison of Pioglitazone and Glipizide Treatment of Type 2 Diabetes
Author(s) -
Basu Ananda,
Basu Rita,
Pattan Vishwanath,
Rizza Robert A.,
Jensen Michael D.
Publication year - 2010
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1038/oby.2010.129
Subject(s) - pioglitazone , glipizide , adipose tissue , medicine , endocrinology , type 2 diabetes , meal , fatty acid , diabetes mellitus , chemistry , biochemistry
Treatment of type 2 diabetes (T2DM) with pioglitazone changes abdominal fat in the opposite direction as treatment with glipizide. To determine whether these two medications affect adipose tissue meal fatty acid storage differently we studied 19 T2DM treated with either pioglitazone ( n = 8) or glipizide ( n = 11) and 11 non‐DM control subjects matched for age, BMI, abdominal and leg fat. A breakfast mixed meal containing [1‐ 14 C]triolein was given and abdominal and femoral subcutaneous (sc) adipose tissue biopsies were collected 6 and 24 h later to measure meal fatty acid storage. The portion of meal fatty acids stored in upper body sc and lower body sc adipose tissue did not differ between non‐DM and T2DM subjects either at 6 or 24 h. Likewise, meal fatty acid storage did not differ between the T2DM participants treated with pioglitazone or glipizide. We conclude that meal fatty acid storage in upper body and lower body sc adipose tissue is not abnormal in T2DM patients treated with pioglitazone or glipizide.